Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $6.4 million.

  • Arrowhead Pharmaceuticals' Depreciation & Amortization (CF) rose 2206.3% to $6.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $25.1 million, marking a year-over-year increase of 2819.03%. This contributed to the annual value of $23.9 million for FY2025, which is 2867.98% up from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Depreciation & Amortization (CF) stood at $6.4 million for Q4 2025, which was up 2206.3% from $6.4 million recorded in Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Depreciation & Amortization (CF) registered a high of $6.4 million during Q4 2025, and its lowest value of $1.9 million during Q1 2021.
  • Its 5-year average for Depreciation & Amortization (CF) is $3.9 million, with a median of $3.6 million in 2023.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Depreciation & Amortization (CF) skyrocketed by 289.13% in 2023, and later surged by 6953.92% in 2024.
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Depreciation & Amortization (CF) stood at $2.6 million in 2021, then rose by 4.51% to $2.7 million in 2022, then soared by 58.53% to $4.3 million in 2023, then increased by 22.8% to $5.2 million in 2024, then rose by 22.06% to $6.4 million in 2025.
  • Its Depreciation & Amortization (CF) was $6.4 million in Q4 2025, compared to $6.4 million in Q3 2025 and $6.2 million in Q2 2025.